NCT05407441View on ClinicalTrials.gov

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2029

Conditions
Atypical Teratoid Rhabdoid TumorINI1 (SMARCB1)-Deficient Primary CNS Malignant TumorsSMARCA4-deficient Primary CNS Malignant TumorsMalignant Rhabdoid Tumor (MRT)Rhabdoid Tumor of the Kidney (RTK)Epithelioid SarcomaChordoma
Interventions
DRUG

Tazemetostat

oral, twice daily, dosage per protocol

DRUG

Nivolumab

IV, dosage and schedule per protocol

DRUG

Ipilimumab

IV, dosage and schedule per protocol

Trial Locations (3)

77030

RECRUITING

Texas Children's Hospital, Houston

02115

RECRUITING

Boston Children's Hospital, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Epizyme, Inc.

INDUSTRY

lead

Susan Chi, MD

OTHER